A key public-input window is about to close. Comments on the FDAs proposal to exclude semaglutide, tirzepatide, and liraglutide from bulk compounding are due by June 29, 2026.
Public comments on the FDAs proposal to exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, the main pathway for large-scale compounding, are due by June 29, 2026. After the window closes, the FDA will weigh input before a final decision. Finalizing the exclusion would sharply reduce compounded GLP-1 availability.
The shrinking space for compounded GLP-1s is approaching a procedural milestone.
By the end of June, the publics chance to weigh in officially closes.
The FDAs proposal, announced April 30 and formalized in a May 1 Federal Register notice, would exclude semaglutide, tirzepatide, and liraglutide from the 503B bulks list, the list of bulk substances outsourcing facilities may use to compound at scale. The agency found no clinical need for bulk compounding of these drugs now that FDA-approved versions are available and shortages have resolved. As of June 2026, the public comment period was in its final stretch, with comments due by June 29, 2026.
Because the underlying shortages were already declared resolved, finalizing the exclusion would remove the main remaining route for large-scale compounding of these GLP-1s, leaving only narrow, patient-specific 503A compounding in limited cases. The FDA will consider submitted comments before issuing a final determination; analysts have suggested a final rule could follow later in 2026.
For consumers, the closing window signals that broadly available compounded GLP-1s are nearing the exit, pending a final rule. Compounded versions are not FDA-approved and have been linked to quality and dosing concerns. As approved products become more accessible, the practical guidance sharpens: prioritize FDA-approved GLP-1s from licensed prescribers and pharmacies, and be cautious of sources still marketing compounded or unbranded versions.
Watch for the comment period to close on June 29 and for the FDAs subsequent final determination, which could substantially reduce compounded supply. Pricing and access for approved products will shape the real-world impact. For individuals using compounded GLP-1s, the prudent step is to discuss FDA-approved alternatives with a prescriber rather than turning to unregulated or online sources as legitimate compounded supply contracts.